Peter S. Nelson

TL;DR: The role of tumor microenvironment components in therapy resistance and the importance of a thorough knowledge of cross talk between tumor cells and microenvironment niches to develop new therapeutic strategies are highlighted.

TL;DR: SPT produces a durable response in AR-pathway inhibitor ENZ CRPC that is associated with sustained suppression of ARv7 and E2F transcriptional outputs, and the DDR transcriptome, highlighting the potential of combination treatments that maintain suppression of these programs to driveA durable response to SPT.

TL;DR: A human neuroendocrine/small cell prostate cancer xenograft that was developed from a nodal metastasis of a human prostate carcinoma and that has been propagated as serial subcutaneous implants in severe combined immunodeficient mice for >4 years should prove to be useful in the investigation of mechanisms underlying the androgen-insensitive state of progressive prostate carcinomas.

TL;DR: It is demonstrated that tight junction architecture in the prostate is related to changes in serum testosterone levels, and an androgen-regulated mechanism that potentially contributes to the development of prostate inflammation and consequent pathology is identified.

TL;DR: It is revealed that dissociation of the eIF4F complex reverses the proliferation program, resulting in decreased tumor growth and improved survival in preclinical models, and a druggable nexus that functionally links the processes of mRNA transcription and translation initiation in an emerging class of lethal AR-deficient prostate cancer.